Actively Recruiting
Study of Monoclonal Antibody Treatments for Aquaporin-4 Positive Neuromyelitis Optica Spectrum Disorder in Adults Aged 18 to 65
Led by Tongji Hospital · Updated on 2025-09-08
200
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness and safety of different monoclonal antibody treatments for people in China who have aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorders AQP4-positive NMOSD. This study focuses on real-world use of these therapies and also aims to track changes in brain imaging and immune system markers before and after treatment. Participants will receive one of several treatments including Inebilizumab, Satralizumab, Eculizumab, Ofatumumab, Rituximab, or conventional immunosuppressive agents. Each participant has confirmed AQP4-positive NMOSD and has agreed to receive one of these monoclonal antibody-based therapies or conventional treatments. During the study, participants will be monitored for up to 96 weeks. Researchers will measure outcomes such as time to first relapse, relapse rates, and disability scores. They will also track new brain lesions on scans and levels of AQP4 antibodies in blood and spinal fluid. Safety and clinical stability will be regularly assessed throughout the trial.
CONDITIONS
Brief Title
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
